CompaniesBiotech & healthDraig Therapeutics Ltd
Download
Company intelligence · Prepared from public filings

Draig Therapeutics Ltd

ACTIVENo. 13405365Incorporated 18 May 2021Cardiffneuroscience therapeutics
Register data as of 27 Aug 2026
12 filings read · view all sources ↓
Watch this company
Raised, filed rounds
£117.0m
Priced rounds
5
Peak step-up
1.6x
Peak implied valuation
£148.6m
Last allotment
Apr 2026
Exhibit 1

Implied valuation at each priced allotment, 2024 to 2026

Implied post-money, GBP · price per share beneath each point · from SH01 filings
£41.6m£83.2m£124.8m£166.4m2024202520265 Sept 2024: £19.5m implied post-money at £1.00 per share9 Jan 2025: £28.5m implied post-money at £1.00 per share10 Jun 2025: £87.1m implied post-money at £1.64 per share18 Jun 2025: £148.6m implied post-money at £1.64 per share30 Apr 2026: £125.5m implied post-money at £1.64 per share£19.5m£1.00/sh£28.5m£1.00/sh£87.1m£1.64/sh£148.6m£1.64/sh£125.5m£1.64/shValuation reads 16% lower on the filed share count; the price did not fall
Source: Companies House, forms SH01 filed by Draig Therapeutics Ltd; Tero analysis. Each point is one filed allotment; click any point to open the underlying filing.
Exhibit 2

Funding rounds, as filed

AllottedShare classPrice / shareRaisedImplied post-moneyStep vs priorSource
30 Apr 2026SERIES A1£1.64£34.6m£125.5m· 1.0xSH01 ↗
18 Jun 2025SERIES A1£1.64£23.1m£148.6m· 1.0xSH01 ↗
10 Jun 2025SERIES A1, SERIES A2£1.64£31.3m£87.1m▲ 1.6xSH01 ↗
9 Jan 2025Seed Preferred£1.00£9.0m£28.5m· 1.0xSH01 ↗
5 Sept 2024Seed Preferred and Ordinary£1.00£19.1m£19.5mfirstSH01 ↗
Total, 5 priced rounds£117.0m
Source: Companies House filing history, company 13405365. Every row links to the filed document it was read from. Prices and share counts as filed; implied post-money is price per share times shares in issue after the allotment.
Methodology
Notes. Raised is the sum of shares allotted times price per share across priced allotments filed on form SH01. Peak step-up is the highest price per share divided by the first priced round. Implied post-money is price per share times shares in issue after the allotment: an approximation that ignores class rights and unexercised options. Allotments classified as option-scheme or nominal issues are excluded from the trajectory.
Primary documents
Every figure on this page is read from a document filed at Companies House and links to it. The full record is public: filing history of Draig Therapeutics Ltd at Companies House ↗. Tero retains an archived copy of each parsed filing. Information, not investment advice.